ArticlePloS one2026
In silico screening and molecular analyses identify apigenin from Scutellaria barbata as a potent AKT1 inhibitor in breast cancer.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BC) remains a leading cause of cancer-related mortality in women worldwide. Scutellaria barbata, a traditional Chinese medicinal herb, possesses recognized anticancer properties, but its mechanistic role in BC is not fully elucidated. This study employed an integrated in silico approach to identify the key flavonoids, targets, and pathways through which S. barbata exerts its anti-BC effects. A multi-step computational methodology incorporating network pharmacology, molecular docking, and dynamics simulations was utilized to profile bioactive compounds from S. barbata. From an initial set of 34 phytocompounds, three flavonoids namely apigenin, 4'-hydroxywogonin, and hispidulin demonstrated favorable drug-likeness, high bioavailability, and low predicted acute oral toxicity (LD₅₀ > 500 mg/kg) profiles. Network analysis identified AKT1, IL6 and TNF as central hub targets, significantly enriched in the PI3K-Akt, MAPK, and TNF signaling pathways. Molecular docking showed strong binding affinities (≤ -7.5 kcal/mol) between these flavonoids and the hub proteins, with hispidulin (-8.1 kcal/mol) and apigenin (-7.7 kcal/mol) exhibiting the highest affinity for AKT1 than other hub proteins. Molecular dynamics simulations over 100 ns further revealed that the apigenin-AKT1 complexes exhibited greater stability with lower RMSD fluctuations, reduced residue flexibility (RMSF), stable radius of gyration, and consistent SASA profiles, compared to other ligands and the control compound. Our computational prediction suggests that apigenin exhibits favorable multi-target interactions with BC-associated proteins. Thus, apigenin may represent a potential candidate for further investigation, particularly with respect to oncogenic signaling pathways involving key hub proteins. However, experimental validation through in vitro and in vivo studies is required to confirm these observations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.